These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35995991)

  • 1. Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.
    Barnay M; Duval F; Solé G; Carla L; Mathis S; Le Masson G
    J Neurol; 2022 Dec; 269(12):6572-6581. PubMed ID: 35995991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
    Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
    PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review.
    Adiao KJB; Espiritu AI; Roque VLA; Reyes JPBT
    J Clin Neurosci; 2020 Feb; 72():316-321. PubMed ID: 31493998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study.
    Pasnoor M; Bril V; Levine T; Trivedi J; Silvestri NJ; Phadnis M; Katzberg HD; Saperstein DS; Wolfe GI; Herbelin L; Higgs K; Heim AJ; Statland JM; Barohn RJ; Dimachkie MM
    Eur J Neurol; 2023 May; 30(5):1417-1424. PubMed ID: 36779862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Beecher G; Anderson D; Siddiqi ZA
    Neurology; 2017 Sep; 89(11):1135-1141. PubMed ID: 28814461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation.
    Bryant A; Atkins H; Pringle CE; Allan D; Anstee G; Bence-Bruckler I; Hamelin L; Hodgins M; Hopkins H; Huebsch L; McDiarmid S; Sabloff M; Sheppard D; Tay J; Bredeson C
    JAMA Neurol; 2016 Jun; 73(6):652-8. PubMed ID: 27043206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
    Dewilde S; Philips G; Paci S; Beauchamp J; Chiroli S; Quinn C; Day L; Larkin M; Palace J; Berrih-Aknin S; Claeys KG; Muppidi S; Mantegazza R; Saccà F; Meisel A; Bassez G; Murai H; Janssen MF
    BMJ Open; 2023 Jan; 13(1):e066445. PubMed ID: 36720569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
    Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
    Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Medication and Long-Term Outcome in Myasthenia Gravis.
    Salins S; Teter B; Kavak K; Wolfe GI; Silvestri NJ
    J Clin Neuromuscul Dis; 2016 Dec; 18(2):61-66. PubMed ID: 27861217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
    Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
    Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting.
    Shivaram S; Nagappa M; Varghese N; Seshagiri DV; Duble S; Siddappa SA; Hesarur N; Sinha S; Taly AB
    Neurol India; 2022; 70(5):1931-1941. PubMed ID: 36352590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.
    Solé G; Mathis S; Friedman D; Salort-Campana E; Tard C; Bouhour F; Magot A; Annane D; Clair B; Le Masson G; Soulages A; Duval F; Carla L; Violleau MH; Saulnier T; Segovia-Kueny S; Kern L; Antoine JC; Beaudonnet G; Audic F; Kremer L; Chanson JB; Nadaj-Pakleza A; Stojkovic T; Cintas P; Spinazzi M; Foubert-Samier A; Attarian S
    Neurology; 2021 Apr; 96(16):e2109-e2120. PubMed ID: 33568541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    Wilf-Yarkoni A; Lotan I; Steiner I; Hellmann MA
    J Neurol; 2021 Oct; 268(10):3871-3877. PubMed ID: 33829320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study.
    Lin J; Li Y; Gui M; Bu B; Li Z
    Ther Adv Neurol Disord; 2024; 17():17562864241251476. PubMed ID: 38751755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Distribution characteristics and correlation analysis of antibody detection value in myasthenia gravis].
    Liu YL; Zheng YM; Luo JJ; Zhang W; Gao F; Yuan Y; Hao HJ
    Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(41):3221-3226. PubMed ID: 31694116
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
    Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis.
    Vijayan J; Menon D; Barnett C; Katzberg H; Lovblom LE; Bril V
    Muscle Nerve; 2021 Oct; 64(4):462-466. PubMed ID: 34235762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.